NOVO — Februar 2026
-
****NOVO: CARGRISEMA VISER VÆGTTAB PÅ 14,2%
-
Novos vægttabshåb Cagrisema viser lovende takter https://proinvestor.com/investornyt/1409696/novos-vaegttabshab-cagrisema-viser-lovende-takter
-
17,2 mia $ CagriSema salg i 2032 https://proinvestor.com/boards/130913
-
"Move over tirzepatide, there’s a new weight loss king for diabetics!!!
Tirzepatide SURPASS-1
~11% average weight loss
30–35% hit ≥10%
≥15% uncommon
≥20% rareCagriSema
~14–15% average
43% hit ≥15%
24% hit ≥20%
No plateau signal". https://x.com/ManOnThePen/status/2018360222901776882 -
Obesity market sales potential tightens as Novo and Lilly enter new era https://www.reuters.com/business/healthcare-pharmaceuticals/obesity-market-sales-potential-tightens-novo-lilly-enter-new-era-2026-02-02/?utm_source=Facebook&utm_medium=Social
-
Video: "On the pen" om Cargrisema : Reimagine 2 er et 68-ugers effekt- og sikkerhedsforsøg, der undersøgte Cagrisema som en kombination af amylinreceptoragonisten Cagrilintid og GLP-1-receptoragonisten Semaglutid i to forskellige doser, 2,4 mg/2,4 mg og 1,0 mg/1,0 mg, hvilket blev målt op mod to forskellige doser af semaglutid (2,4 mg og 1,0 mg), Cagrilintid (2,4 mg) og placebo.
Forsøget omfattede 2728 personer med type 2-diabetes. https://proinvestor.com/boards/130920 -
Starter ved 8 min.
-
junklau: "Following the results of REIMAGINE 1 and REDEFINE 3, Novo Nordisk will approach authorities to discuss the regulatory pathway for CagriSema in type 2 diabetes". https://ml-eu.globenewswire.com/Resource/Download/1ee4bf75-6328-45d9-8a8f-d4d3603b89d3
-
Novo Nordisk Stock Breakdown : https://x.com/DrewCohenMoney/status/2018340318777573468
-
NOVO har indsendt ansøgning om godkendelse af Wegovy-pille i Brasilien.
Det er også vigtigt at bemærke, at selvom patentet for semaglutid udløber i marts 2026, er oral Wegovy (Rybelsus og Wegovy-pille) stadig beskyttet af formuleringspatenter. https://www.novonordisk.com.br/content/nncorp/br/pt/noticias-e-imprensa/busca-noticias/novo-nordisk-submete-wegovy-comprimidos-semaglutida-oral-25-mg-para-tratamento-da-obesidade-a-aprovacao-regulatoria-da-anvisa.html
-
Jyske Bank: Novo Nordisk står over for et historisk år med udsigt til negativ vækst https://proinvestor.com/investornyt/1410012/jyske-bank-novo-nordisk-star-over-for-et-historisk-ar-med-udsigt-til-negativ-vaekst
-
Is Novo Nordisk Stock a Bargain Right Now? https://finance.yahoo.com/news/novo-nordisk-stock-bargain-now-190800470.html?guccounter=1&guce_referrer=aHR0cHM6Ly90LmNvLw&guce_referrer_sig=AQAAANadp33ALtrGqEzqQkREWV4Kr5ubL5cOgoqLrHNdDgyEFTpR2ZwfDjVVhK1cqzuYT3TrUdWlpw4RkezuolpXLTxHSh_-NxFhu53bFkqe9L--klR4z4uH2OdWHGvUsxpJAheRcqtLkeBGQrzsMDKIiZWs40Wtp3qymZzToI-kQDsw
-
Pfizer dykker på data for vægttabsmiddel fra Metsera-opkøb https://proinvestor.com/investornyt/1410105/pfizer-dykker-pa-data-for-vaegttabsmiddel-fra-metsera-opkob
-
Company announcement No 03 / 2026
Novo Nordisk releases 2026 sales and operating profit outlook https://ml-eu.globenewswire.com/Resource/Download/41efd6dd-ee18-4568-980c-df6bb715145a -
Novo Nordisk
releases 2026 sales and operating profit outlook https://proinvestor.com/boards/130939
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind